Starpharma (ASX: SPL, OTCQX: SPHRY) today announces it has entered into a strategic partnership with Medicxi, a leading life sciences investment firm dedicated to financing companies developing innovative medicines, to co-found a new UK-based company called Petalion Therapeutics Limited (“Petalion”).Petalion will initially focus on developing novel targeted dendrimer-drug conjugate therapies in oncology, utilising Starpharma’s proprietary DEP® dendrimer platform technology.Medicxi will fund Petalion with an initial investment of up to USD $25 million (~AUD $38 million) to finance the development of a novel oncology drug candidate.

Starpharma（ASX:SPL，OTCQX:SPHRY）今天宣布，它已与Medicxi（一家致力于为创新药物开发融资的领先生命科学投资公司）建立战略合作伙伴关系，共同成立了一家总部位于英国的新公司，名为Petalion Therapeutics Limited（“Petalion”）。Petalion最初将利用Starpharma专有的DEP®树枝状聚合物平台技术，专注于开发肿瘤学中新型靶向树枝状聚合物-药物偶联疗法。Medicxi将为Petalion提供高达2500万美元（约3800万澳元）的初始投资，以资助新型肿瘤候选药物的开发。

Starpharma will license certain intellectual property (“IP”) to Petalion as required for the research, development, manufacture and commercialisation of this potential new therapeutic and, in exchange, will receive an equity holding of 22.5% in Petalion.Collaboration AgreementUnder the terms of the collaboration, Starpharma will license the IP to Petalion on an exclusive basis for a mutually agreed target.

Starpharma将根据研究、开发、制造和商业化这种潜在的新型治疗药物的需要，向Petalion授予某些知识产权（“IP”），作为交换，将获得Petalion 22.5%的股权。合作协议根据合作条款，Starpharma将根据双方商定的目标，以排他性方式将知识产权许可给Petalion。

In consideration for the IP licence to this specific target, Starpharma will be issued ordinary shares in Petalion. Starpharma will also provide R&D services to Petalion on a fee for service basis.Medicxi intends to finance Petalion’s development program via a tranched investment plan with defined scientific and technical milestones, culminating in a total investment of up to USD $25 million.Dr Mehdi Shahidi, a highly experienced pharmaceutical executive, has been appointed as CEO of Petalion.

考虑到这一特定目标的知识产权许可，Starpharma将发行Petalion的普通股。Starpharma还将向Petalion提供按服务收费的研发服务。Medicxi打算通过一项分期投资计划为Petalion的发展计划提供资金，该计划具有明确的科学和技术里程碑，最终总投资高达2500万美元。经验丰富的制药高管MehdiShahidi博士被任命为Petalion的首席执行官。

A clinical oncologist by background, Dr Shahidi has over two decades of experience in pharmaceutical drug development, most recently as Corporate Senior Vice President, Chief Medical Officer, and Global Head of Medicine at Boehringer Ingelheim.Dr Mehdi.

沙希迪博士是一名临床肿瘤学家，拥有20多年的药物开发经验，最近担任勃林格殷格翰公司高级副总裁、首席医疗官和全球医学主管。Mehdi博士。